↓ Skip to main content

Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused?

Overview of attention for article published in BMC Medicine, July 2017
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (98th percentile)
  • High Attention Score compared to outputs of the same age and source (94th percentile)

Mentioned by

news
5 news outlets
blogs
4 blogs
policy
3 policy sources
twitter
168 X users

Citations

dimensions_citation
182 Dimensions

Readers on

mendeley
221 Mendeley